FILING ANALYSIS · THURSDAY, NOVEMBER 5
Amphastar Pharmaceuticals, Inc. AMPH — 8-K: Results of Operations and Financial Condition
neutral
Amphastar reported Q3 net revenues of $207.6 million, a 8% increase from the prior year, driven by growth in BAQSIMI and Primatene MIST sales, with GAAP net income of $37.8 million, or $0.87 per share, and adjusted non-GAAP net income of $49.3 million, or $1.14 per share.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →